Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. heart tissue
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Heart Tissue Articles & Analysis

27 news found

Mastering Tissue Dissociation - Episode 1 : The Heart

Mastering Tissue Dissociation - Episode 1 : The Heart

The dissociation of mouse heart tissue into single cells is a crucial step in many biomedical investigations. ...

ByBertin Technologies


CD BioSciences Announces Comprehensive Circulatory System Tissue Microarrays

CD BioSciences Announces Comprehensive Circulatory System Tissue Microarrays

These new Circulatory System Tissue Microarrays, including Heart & Vascular Tissue Microarrays and Spleen Tissue Microarrays, are designed to accelerate research into heart disease, vascular disorders, and other conditions affecting the circulatory system. ...

ByCD BioSciences


BIO Investor Forum Company Snapshot: InvivoSciences

BIO Investor Forum Company Snapshot: InvivoSciences

IVS’s Functional 3D tissue models recapitulate the physiological properties of human cardiac, smooth and skeletal muscle and connective tissue. ...

ByInvivoSciences, Inc. (IVS)


Presenting Monogenic Heart Failure Disease Modeling in Kyoto

Presenting Monogenic Heart Failure Disease Modeling in Kyoto

https://www.termis.org/wc2018/ On September 7th, CSO speaks about monogenic disease modeling using NuHeart™ technology during TERM for heart, blood vessel & lung session. 99-O-5: Personalized micro-3D human heart tissues for orphan drug development Tetsuro Wakatsuki,Neil Daily,Pinar Kemanli, Michael Greenberg,Jennifer Strande ...

ByInvivoSciences, Inc. (IVS)


BIOtechNOW featured IVS’s participating BIO Innovation Zone

BIOtechNOW featured IVS’s participating BIO Innovation Zone

IVS’s functional 3D tissue models reconstitute the physiological properties of human cardiac, smooth and skeletal muscle as well as connective tissues that support cancer growth. Our lead product is 3D cardiac engineered heart tissues (EHTs) fabricated from human induced pluripotent stem cell (iPSC) derived cardiomyocytes. ...

ByInvivoSciences, Inc. (IVS)


BMG LABTECH and InvivoSciences, Inc. Initiate Market Collaboration To Accelerate Drug Discovery in Engineered 3D Tissues

BMG LABTECH and InvivoSciences, Inc. Initiate Market Collaboration To Accelerate Drug Discovery in Engineered 3D Tissues

The Microplate Reader Company – and InvivoSciences, Inc. – a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery – announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader ...

ByInvivoSciences, Inc. (IVS)


Valo Health - FDA Collaborative Study in Human Cardiac Tissues Demonstrates Potential to Predict Clinical Efficacy of Cardiac Contractility Modulation Devices to Treat Heart Failure

Valo Health - FDA Collaborative Study in Human Cardiac Tissues Demonstrates Potential to Predict Clinical Efficacy of Cardiac Contractility Modulation Devices to Treat Heart Failure

Valo Health, Inc (“Valo”) shared the ini­tial results of a col­lab­o­ra­tive study with the U.S. Food and Drug Admin­is­tra­tion (FDA), demon­strat­ing the poten­tial of Val­o’s Biowire plat­form to pre­dict clin­i­cal effi­ca­cy of Car­diac Con­trac­til­i­ty Mod­u­la­tion ...

ByValo Health, Inc.


XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

The company also plans other clinical studies in additional cardiovascular indications, including heart failure caused by ischemic heart disease and as adjunctive therapy to percutaneous coronary intervention. ...

ByXyloCor Therapeutics


XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease

XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease

XC001 is designed to promote new blood vessels in the heart that will bypass diseased blood vessels and improve blood flow. ...

ByXyloCor Therapeutics


Lineage Broadens Collaboration With Advanced BioMatrix for HyStem Cell Drug Delivery Technology

Lineage Broadens Collaboration With Advanced BioMatrix for HyStem Cell Drug Delivery Technology

HyStem is a patented hydrogel which mimics naturally occurring extracellular matrix, the structural network of molecules surrounding cells in organs and tissues and essential to cellular function and tissue structure. HyStem biomaterial has been shown to support cellular attachment and survival as well as compatibility with a wide variety of cells and ...

ByLineage Cell Therapeutics, Inc.


XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT

XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT

The investigational gene therapy is administered directly to the heart muscle through a mini-thoracotomy by an experienced cardiac surgeon. ...

ByXyloCor Therapeutics


XyloCor Therapeutics Expands Leadership Team with Accomplished Pharmaceutical Executives to Accelerate Clinical Development Programs and Drive Corporate Growth

XyloCor Therapeutics Expands Leadership Team with Accomplished Pharmaceutical Executives to Accelerate Clinical Development Programs and Drive Corporate Growth

XyloCor has a second preclinical investigational product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. The company, which was co-founded by Ronald Crystal, MD, and Todd Rosengart, MD, has an exclusive license from Cornell ...

ByXyloCor Therapeutics


BIOMODEX and Montreal Heart Institute Team Up to Develop 3D Printed Pulsatile Heart Models

BIOMODEX and Montreal Heart Institute Team Up to Develop 3D Printed Pulsatile Heart Models

"Physicians often tell us they are impressed by how well our structural heart solution simulates the feel, friction, and haptic feedback of real heart tissue and blood vessels. ...

ByBIOMODEX


First-in-Human Trial of Pulsed Field Ablation with Kardium’s Globe® PF System

First-in-Human Trial of Pulsed Field Ablation with Kardium’s Globe® PF System

Pulsed field ablation is an innovative therapy that uses electric fields to treat heart tissue. PFA delivered by the Globe PF System is unique in that it achieves true single-shot isolation; a single application of the GlobePulse™ Waveform achieves pulmonary vein isolation (PVI) in as little as 3 seconds. The Globe PF System also provides high-definition ...

ByKardium Inc.


Acutus Medical Initiates CE Mark Study for Focal Pulsed Field Ablation Therapy to Treat Atrial Fibrillation

Acutus Medical Initiates CE Mark Study for Focal Pulsed Field Ablation Therapy to Treat Atrial Fibrillation

This approach is different from many others entering this field, in that it will allow precise applications of PFA in highly targeted tissue across the full range of arrhythmias, including atrial fibrillation and flutter and atrial and ventricular tachycardias – while preserving as much fully functional cardiac tissue as possible. ...

ByAcutus Medical, Inc.


XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease

XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease

About XC001 XC001 is an investigational gene therapy designed to promote the growth of new blood vessels in the heart, with these new blood vessels bypassing diseased blood vessels and improving blood flow in the heart. ...

ByXyloCor Therapeutics


Boston Scientific Exercises Option to Acquire Farapulse, Inc.

Boston Scientific Exercises Option to Acquire Farapulse, Inc.

Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific electrophysiology portfolio to include the FARAPULSE Pulsed Field Ablation (PFA) System – a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. ...

ByBoston Scientific


Philip Morris International and TissUse develop a human aerosol test platform to emulate the entire human respiratory tract

Philip Morris International and TissUse develop a human aerosol test platform to emulate the entire human respiratory tract

PMI and TissUse have signed a collaboration agreement to utilize PMI’s InHALES technology in combination with TissUse’s proprietary Multi-Organ-Chip (MOC) platform to enable inhalation exposure of functional human tissues in homeostasis at minute scale in vitro. The two partners will develop a highly innovative integrated human aerosol test platform that emulates the entire human ...

ByTissUse GmbH


The Ultimate List of Attractive MedTech M&A Targets

The Ultimate List of Attractive MedTech M&A Targets

Once in position, the balloon is inflated cyclically and used to intermittently block the coronary sinus outflow in order to ensure blood reaches the ischemic heart tissue. Balloon deflation helps wash out harmful agents from the microcirculation. ...

ByAnuncia Medical, Inc.


FARAPULSE’s Pivotal ADVENT Trial underway with First Patients Treated with its Breakthrough Pulsed Field Ablation System to Treat Atrial Fibrillation

FARAPULSE’s Pivotal ADVENT Trial underway with First Patients Treated with its Breakthrough Pulsed Field Ablation System to Treat Atrial Fibrillation

Traditionally, the tip of an ablation catheter generates extreme temperatures -hot or cold - to eliminate the targeted heart tissue associated with irregular heartbeats. The PFA system, however, relies on non-thermal electric fields that are tissue-selective. That is, PFA selectively ablates heart tissue without ...

ByBoston Scientific

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT